Category Archives: Myocardial Infarction

Background In survivors of acute ST-segment-elevationmyocardial infarction(STEMI), increased aortic stiffness is associated with worse clinical outcome; however, the underlying pathomechanisms are incompletely understood. We aimed to investigate associations between aortic stiffness and infarct healing using comprehensive cardiac magnetic resonance imaging in patients with acute STEMI. This was a prospective observational study including 103 consecutive STEMI patients treated with primary percutaneous coronary intervention. Continue reading →

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Apabetalone is a first-in-class, small molecule, bromodomain and extraterminal domain (BET) inhibitor that selectively targets bromodomain 2 (BD2) at the transcription level Continue reading →

Heart attacks often have a classic roster of symptoms: chest pain, shortness of breath, and the sensation of something heavy on the chest. But not always. Silent heart attacks, more formally known as a silent myocardial infarction (SMI), are "silent" because symptoms are so mild that people often do not realize they occurred Continue reading →

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Apabetalone is a first-in-class, small molecule, bromodomain and extraterminal domain (BET) inhibitor that selectively targets bromodomain 2 (BD2) at the transcription level Continue reading →

Jens Ellingsen, 1 Gunnar Johansson, 2 Kjell Larsson, 3 Karin Lisspers, 2 Andrei Malinovschi, 4 Bjrn Stllberg, 2 Marcus Thuresson, 5 Christer Janson 1 1Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden; 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 3Integrative Toxicology, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 4Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden; 5Statisticon AB, Uppsala, Sweden Correspondence: Jens Ellingsen Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Akademiska Sjukhuset, Uppsala SE-751 85, Sweden Tel +46 18 611 13 93 Fax +46 18 611 02 28 Email jens.ellingsen@medsci.uu.se Background: Life expectancy is significantly shorter for patients with chronic obstructive pulmonary disease (COPD) than the general population. Concurrent diseases are known to infer an increased mortality risk in those with COPD, but the effects of pharmacological treatments on survival are less established. Continue reading →

The heart is the most vital organ of the body that pumps blood to every other organ. Any aberration in the normal functioning of the heart can lead to serious pathological conditions which might permanently impact the functioning of other organs. At present, heart attack or myocardial infarction has become a critical global health issue Continue reading →

Abstract BACKGROUND: There is a paucity of population-based geospatial data about the association between active transport andmyocardial infarction. We investigated the association between active transport to work and incidence ofmyocardial infarction. Continue reading →

1. The ISCHEMIA Trial The ISCHEMIA trial transcends the cath lab and influences much of cardiology practice. Its findings also reach into human psychology. Continue reading →

BACKGROUND: Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. Continue reading →

The Food and Drug Administration (FDA) has approved the use of Vascepa (icosapent ethyl; Amarin Pharma) as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (150mg/dL) and established CV disease or diabetes mellitus and 2 or more additional risk factors for CV disease. The approval was based on data from the phase 3 REDUCE-IT trial that assessed the CV outcomes of 8179 patients who were administered Vascepa as an add-on to statins, and who had elevated TG levels (135mg/dL) with either CV disease or diabetes and other CV risk factors. The primary composite end point included time to first occurrence of CV death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina (5-point major adverse cardiovascular event [MACE]) Continue reading →